Ozmosi | AMX-0318 Drug Profile
Drug Profile
Using advanced filters...

AMX-0318

Alternative Names: AMX-0318, AMX0318, AMX 0318
Clinical Status: Active
Latest Update: 2026-11-06
Latest Update Note: Clinical Trial Update

Product Description

(Sourced from: https://www.benzinga.com/pressreleases/26/11/b62910545/amylyx-pharmaceuticals-reports-third-quarter-2026-financial-results)

Mechanisms of Action: GLP-1 Antagonist

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Amylyx Pharmaceuticals
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 0: Hypoglycemia

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

Recent News Events

Date

Type

Title